Transdermal Or Percutaneous Patents (Class 424/449)
-
Patent number: 7588784Abstract: Onions (Allium Cepa and its close relatives, as opposed to Allium Sativum) contain potent coagulation modulators, as well as platelet inhibitors. Clinical, in vivo and in vitro testing confirms that the efficacy of commonly consumed quantities of onions in terms of the efficacy of its impact on coagulation and platelet function rivals and in many respects exceeds the potency of any other modalities available today. Additionally, onion compounds have unique effects as described later in this application.Type: GrantFiled: October 5, 2007Date of Patent: September 15, 2009Inventors: Attila Mady, Juliana Mady
-
Publication number: 20090226507Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to topically or transdermally administered pharmacologically or cosmeceutically active agents. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Topically applied formulations and drug delivery devices employing hydroxide-releasing agents as permeation enhancers are provided as well.Type: ApplicationFiled: October 8, 2008Publication date: September 10, 2009Inventors: Eric C. Luo, Eric C. Jacobson, Tsung-Min Hsu
-
Patent number: 7585519Abstract: Esters of L-carnitine and alkanoyl L-carnitines are described which can be used as cationic lipids for the intracellular delivery of pharmacologically active compounds. New esters of L-carnitine and alkanoyl L-carnitines of formula (I) are also disclosed wherein the R groups are as defined in the description.Type: GrantFiled: March 27, 2007Date of Patent: September 8, 2009Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Claudio Pisano, Maria Ornella Tinti, Mosé Santaniello, Luciana Critelli, Giovanni Salvatori
-
Publication number: 20090220580Abstract: The present invention provides a percutaneous absorption formulation including a patch having an adhesive layer disposed on a substrate and the adhesive layer contains ketotifen fumarate and tris(hydroxymethyl)aminomethane, and the patch is packaged in a hygroscopic packaging material. In the percutaneous absorption formulation, tris(hydroxymethyl)aminomethane particularly selected from various basic substances is incorporated, and by packaging the patch in a hygroscopic packaging material, the percutaneous absorptivity and content stability of a drug can be simultaneously improved and the yellowing of the drug can be suppressed. These effects can be further improved by the incorporation of propyl gallate, the use of an adhesive layer including an SIS-based adhesive base and a rosin ester-based adhesion imparting resin, and/or the removal of oxygen from the atmosphere in the inside of the packaging material.Type: ApplicationFiled: April 20, 2005Publication date: September 3, 2009Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Kouji Kawahara, Yasuhiko Aramomi, Noriko Shimada, Akira Ohtori, Akiharu Isowaki
-
Publication number: 20090214624Abstract: The present invention is related to topical nitric oxide delivery systems, and to using the same for mitigating or remediating various disease states The present invention is also related to using topical nitric oxide delivery systems for enhancing blood flow.Type: ApplicationFiled: November 29, 2005Publication date: August 27, 2009Applicant: THE UNIVERSITY OF AKRONInventors: Daniel J. Smith, Marco Lopez, Patricio Lopez-Jaramillo
-
Publication number: 20090214625Abstract: The site to which a patch was stuck may be identified even after the patch is removed. A patch for drug delivery includes a drug holding portion and a backing layer. The patch further includes a marker capable of indicating a site to which the patch was stuck even after the patch is removed therefrom.Type: ApplicationFiled: July 18, 2006Publication date: August 27, 2009Inventors: Mizuo Nakayama, Akihiko Matsumura, Takehiko Matsumura, Hidero Akiyama
-
Publication number: 20090208561Abstract: The present invention relates to a transdermal therapeutic system for the controllable release of an active ingredient, particularly a substance promoting wound healing, to a chronic wound or for chemotherapy, with at least one waveguide, wherein the active ingredient is deposited on the waveguide via a bond that is cleavable by electromagnetic pulses in the waveguide.Type: ApplicationFiled: April 5, 2007Publication date: August 20, 2009Inventors: Katrin Schmitt, Christian Hoffmann
-
Patent number: 7574256Abstract: An iontophoresis device includes: an active electrode element operable to provide an electrical potential; an inner active agent reservoir comprising: a first compartment having a diluent; a second compartment having an active agent; and a polymer complex layer disposed between the first compartment and the second compartment, the polymer complex being formed by a first hydrophilic polymer and a second hydrophilic polymer via hydrogen bonding. The polymer complex is electrically responsive and disintegrates when an electrical field is applied.Type: GrantFiled: September 27, 2006Date of Patent: August 11, 2009Assignee: TTI ellebeau, Inc.Inventor: Darrick Carter
-
Publication number: 20090196911Abstract: A silicone acrylate hybrid composition includes the reaction product of a silicon-containing pressure sensitive adhesive composition, an ethylenically unsaturated monomer, and an initiator. The silicon-containing pressure sensitive adhesive composition includes acrylate or methacrylate functionality. A method of making the hybrid composition includes polymerizing the ethylenically unsaturated monomer and the silicon-containing pressure sensitive adhesive composition in the presence of the initiator.Type: ApplicationFiled: June 6, 2007Publication date: August 6, 2009Inventors: Gary L. Loubert, Timothy Mitchell, Xavier Jean-Paul Thomas
-
Publication number: 20090186072Abstract: An active transdermal medicament patch includes a planar substrate with a therapeutic face releasably retainable against the skin of a patient. A return electrode and a medicament matrix susceptible to permeation by medicament are secured at separated locations on the therapeutic face and electrically conductively engage the skin. A detector monitors iontophoretic medicament migration into the skin. An integrator operating on the output of the detector produces a running cumulative total of the amount of medicament delivered during a plurality of temporally non-contiguous therapy subsessions. A circuit breaker terminates medicament migration, when the output of the integrator equals a predetermined medicament quantity. A timer active during medicament migration stimulates a driver to operate a light-emitting diode in a distinct delivery confirmation mode during each a sequence of non-overlapping predetermined therapy subsessions, respectively.Type: ApplicationFiled: January 18, 2008Publication date: July 23, 2009Inventor: Jamal S. Yanaki
-
Publication number: 20090181075Abstract: A transdermal drug delivery device comprising an adhesive matrix, an effective amount of drospirenone, and an oligomeric adjuvant selected from an oligolactic acid, oligolactic acid derivatives, or mixtures thereof. Also, a transdermal drug delivery device comprising a backing film and an adhesive matrix which comprises an effective amount of drospirenone, a solubilizing agent, and a permeation enhancer selected from the group consisting of alkyl lactates, carboxylic acids, alkyl esters of fatty acids, and mixtures thereof.Type: ApplicationFiled: July 13, 2006Publication date: July 16, 2009Inventors: Ryan D. Gordon, Peter M. Seiler, Donald T. Landin, Stefan Bracht, Wolfgang Eder
-
Patent number: 7560121Abstract: A transdermal therapeutic system consisting of a backing layer, at least one active substance-containing matrix layer, which may at the same time possess pressure-sensitive adhesive properties, as well as a removable protective layer is characterized by a content of a neuroleptic, a content of at least one permeation enhancer as well as by a layer which is pressure-sensitive adhesive on the skin-facing side and based on polymers which are pure hydrocarbons.Type: GrantFiled: April 7, 2000Date of Patent: July 14, 2009Assignee: LTS Lohmann Therapie-Systeme AGInventors: Stefan Bracht, Michael Horstmann
-
Publication number: 20090175927Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. This invention relates to the use of cells and cellular extracts in rejuvenation and healing technologies thereby improving healing and regeneration of all bodily tissues and organs. The present invention relates to compositions and methods of managing, preventing, and treating scars. The invention also relates to prevention of deterioration, damage and malfunction of cells and tissues, and to promote, improve or exceed cellular function in order to promote, improve and exceed appearance, vitality and health. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products. Said components can also be synthesized.Type: ApplicationFiled: May 11, 2007Publication date: July 9, 2009Applicant: Regenics A/SInventors: Runhild Gammelsaeter, Jan Remmereit
-
Publication number: 20090175928Abstract: The invention relates to a self-adhesive lip plaster which comprises at least one single-layered matrix and which contains at least one antiviral active medical substance for using in the event of Herpes labialis. Said matrix is arranged on a flexible carrier film which is hydrophobic and also permeable to vapor.Type: ApplicationFiled: October 9, 2006Publication date: July 9, 2009Inventors: Stephan Maier, Ulrike Vollmer
-
Publication number: 20090175929Abstract: Disclosed is a donepezil-containing transdermally absorbable preparation which develops reduced adverse side effects and shows a satisfactory level of therapeutic effect. The preparation comprises an adhesive and a donepezil component (containing crystalline donepezil having type-B crystal polymorphism) and/or a salt thereof, wherein the donepezil component or the salt thereof is contained in an amount of 9 to 50% by mass relative to the total weight of the adhesive. The preparation (particularly, one having a non-aqueous adhesive layer) shows an excellent penetration of donepezil and/or a salt thereof into the skin, retains good stability of the active ingredient therein, and is remarkably reduced in local stimulation and adverse side effects.Type: ApplicationFiled: May 8, 2007Publication date: July 9, 2009Inventors: Takaaki Terahara, Yasunari Michinaka, Kazunosuke Aida, Masaru Nakanishi, Wataru Hattori, Takao Kuroda
-
Patent number: 7556824Abstract: The present invention provides novel transdermal patch comprising a therapeutic amount of a hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate in therapeutically effective dosage of each of the aforementioned compounds.Type: GrantFiled: October 7, 2003Date of Patent: July 7, 2009Assignee: NitroMed, Inc.Inventors: Joseph Loscalzo, Joseph A. Vita, Michael D. Loberg, Manuel Worcel
-
Patent number: 7556823Abstract: Silicone adhesive formulations are provided, in which fentanyl particles are suspended in one or more solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.Type: GrantFiled: October 28, 2008Date of Patent: July 7, 2009Assignee: Mylan Pharmaceuticals, Inc.Inventors: Kenneth J. Miller, II, Sharad K. Govil, Kuljit Singh Bhatia
-
Publication number: 20090169606Abstract: The invention relates to a tobacco alkaloid patch for transdermal administration of a tobacco alkaloid, said patch comprising an impermeable backing (17) and a membrane (14) which defines a reservoir (12) there between, said membrane (14) being permeable to and in contact with said tobacco alkaloid, said impermeable backing (17) and said membrane (14) being at least partly joined by a sealing (11), wherein said patch has a flexural strength of less than about 250 mN/mm. According to an advantageous embodiment of the invention, very high-dose nicotine patches may be obtained having acceptable membrane areas and featuring acceptable user comfort.Type: ApplicationFiled: December 8, 2005Publication date: July 2, 2009Applicant: Fertin PharmaInventors: Jesper Kruse Andersen, Merle Lotte Conradi-Larsen
-
Publication number: 20090156982Abstract: A treatment device for treating a medical condition comprises a composition selected for its ability to treat the medical condition, the composition being formulated for transdermal delivery. A portable container is provided which comprises a body for accommodating the composition in a sealed arrangement, a frangible seal on the container which can be ruptured to enable discharge of the composition from the body, and an application component on the container for facilitating transdermal delivery of the composition.Type: ApplicationFiled: September 5, 2008Publication date: June 18, 2009Inventors: Arezou Petrie, Louis Petrie, Xavier Roy
-
Publication number: 20090155343Abstract: A tamsulosin-containing transdermal patch. A transdermal patch comprising a backing-layer and an adhesive layer on the backing-layer, characterized in that the adhesive layer contains an acrylic adhesive, further contains tamsulosin as an active ingredient in an amount of 0.1 to 20% by mass of the total mass of the adhesive layer and, if desired, a polyoxyethylene alkyl ether which is an additive playing a role in increasing solubility and a propylene glycol fatty acid ester which is an additive playing a role in promoting percutaneous absorption is provided. Further, a transdermal patch comprising a backing-layer and an adhesive layer on the backing-layer, characterized in that the adhesive layer contains a synthetic rubber adhesive, further contains tamsulosin as an active ingredient in an amount of 0.1 to 20% by mass of the total mass of the adhesive layer and a propylene glycol fatty acid ester which is an additive playing a role in promoting percutaneous absorption is provided.Type: ApplicationFiled: April 3, 2007Publication date: June 18, 2009Applicant: NICHIBAN CO., LTDInventors: Kouji Kawahara, Kenichi Nakao, Haruna Yamaki
-
Publication number: 20090142390Abstract: A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.Type: ApplicationFiled: November 17, 2008Publication date: June 4, 2009Applicant: Mylan LaboratoriesInventors: Kristin Jackson, Kenneth J. Miller, II
-
Publication number: 20090130190Abstract: Methods and systems for the transdermal delivery of sufentanil and its analogs are described, from patches having a unique pharmacodynamic profile that can be used to treat persistent pain over extended periods and acute pain episodes of limited duration.Type: ApplicationFiled: October 21, 2008Publication date: May 21, 2009Applicant: LABTEC GMBHInventors: Armin Breitenbach, Peter Klaffenbach, Ingo Lehrke, Ulrike Vollmer
-
Publication number: 20090130189Abstract: Devices for transdermal administration of nicotine, which provide for basic as well as additional user activatable administration of nicotine, as well as use of such devices.Type: ApplicationFiled: March 10, 2005Publication date: May 21, 2009Applicant: PFIZER HEALTH ABInventors: Fredrik Nicklasson, Kristina Thyresson, Katarina Lindell
-
Publication number: 20090123528Abstract: The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others.Type: ApplicationFiled: January 16, 2009Publication date: May 14, 2009Applicant: Strategic Science & Technologies, LLCInventor: Eric Thor Fossel
-
Publication number: 20090123527Abstract: Disclosed is a method of inducing topical anesthesia in a tissue or organ of an animal comprising providing an aqueous gel formulation comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed are a transdermal patch comprising the aqueous gel formulation suitable for applying on the skin of a patient and a method of controlling pain therewith.Type: ApplicationFiled: January 15, 2009Publication date: May 14, 2009Applicant: Akorn, Inc.Inventors: ABU ALAM, Elias Reichel, Brandon Busbee
-
Patent number: 7527802Abstract: A vaccine delivered by transcutaneous immunization provides an effective treatment against infections by pathogens such as, for example, enterotoxigenic Escherichia coli (ETEC) and/or for symptoms of diarrheal disease caused thereby. For example, one, two, three, four, five or more antigens derived from ETEC and capable of inducing an antigen-specific immune response (e.g., toxins, colonization or virulence factors) and one or more optional adjuvant (e.g., whole bacterial ADP-ribosylating exotoxins, B subunits or toxoids thereof, detoxified mutants and derivatives thereof) are used to manufacture vaccines or to induce systemic and/or mucosal immunity.Type: GrantFiled: February 13, 2002Date of Patent: May 5, 2009Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Gregory M. Glenn, Frederick J. Cassels
-
Publication number: 20090110718Abstract: New derivatives of tiacumicin B are disclosed and are presented by the general formula: wherein R is The use of these derivatives as a method for treating cancer or tumor is disclosed. A method of treating cancer or tumor by administrating the patient a composition comprising a therapeutically effective amount of the tiacumicin B is also disclosed.Type: ApplicationFiled: February 25, 2008Publication date: April 30, 2009Applicant: Echem Hightech Co., Ltd.Inventors: Mei-Chiao Wu, Chang-Cheng Huang, Yi-Chen Lu, Wei-Jen Fan
-
Publication number: 20090104253Abstract: A hemostatic biocidal dressing includes pro-coagulant and biocidal agents providing a physical barrier to bleeding as well as chemical action to promote blood coagulation and thereby arrest coverage. At the same time, biocidal properties of the dressing prevent the introduction of infected agents and the establishment of infection within wounded tissue. A silverized textile provides biocidal action while a granulated hemostatic agent disposed within interstitial regions between polymer fibers provides coagulating action.Type: ApplicationFiled: June 4, 2008Publication date: April 23, 2009Inventors: G. Alan Thompson, Richard Eward Brois, SR., Christopher Matthew Scheuerman, SR., David Curry Pitts, JR.
-
Patent number: 7521065Abstract: Compositions are provided for the topical treatment of cancer consisting of lotions, creams, sprays, suppositories or slow-release transdermal patches containing lipid-soluble, skin-penetrating organic selenium compounds in combination with inert carriers in therapeutically effective amounts of selenium compound. The selenium compounds are medium linear chain dialkyl diselenides and precursors such as alkyl selenols. Preferred compositions employ R—Se—Se—R compounds where R is from 6 to 8 carbon atoms, and most specifically di-n-hexyl diselenide. Commonly used carriers may be purified hydrocarbon fractions, oils, with or without added fat-soluble vitamins, water and emulsifying agents.Type: GrantFiled: December 7, 2004Date of Patent: April 21, 2009Inventor: Gerhard N. Schrauzer
-
Patent number: 7507769Abstract: The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents formation of benign breast conditions that can lead to cancer.Type: GrantFiled: March 22, 2004Date of Patent: March 24, 2009Assignee: Laboratoires Besins InternationalInventor: Elisabeth Le Nestour
-
Publication number: 20090074846Abstract: A patch containing a medicament comprises a release paper oppositely lying on the surface of a patch carrier. The release paper is defined to, from right to left, a first teardown slice, a second teardown slice, and a third teardown slice. Each teardown slice correspondingly matches with an adjacent edge of another teardown slice through joints of concaves and convexes. The second teardown slice is close to the adjacent edges of the first teardown slice and third teardown slice, in which two pairs of smaller convex unit margins are oppositely symmetrical, and between the two pairs of smaller convex unit margins, each pair of larger concave unit margins are oppositely symmetrical to make the release paper stably and securely adhere to a carrier. For the functional effect of a product, the curve is unlikely complicated making a trouble to a user in tearing down the patch.Type: ApplicationFiled: August 4, 2008Publication date: March 19, 2009Inventor: Connie Hsu
-
Publication number: 20090074845Abstract: A transdermal active principle delivery means comprises a skin adherent or otherwise skin-tolerant substrate applicable to a skin area affected by DNA virus, which substrate includes a composition for treating DNA comprising a transdermally effective carrier medium including at least one active principle selected from the group consisting of diuretic agents and/or cardiac glycoside agents.Type: ApplicationFiled: August 22, 2006Publication date: March 19, 2009Applicant: HENDERSON MORLEY PLCInventors: Ian Stuart Pardoe, Christopher Hartley
-
Publication number: 20090074844Abstract: The present invention relates to a blood concentration regulation type percutaneous absorption preparation, which comprises an ester form of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-oxocyclopentyl)ethyl]sulfanyl}butanoic acid and a base for external preparations. The blood concentration regulation type percutaneous absorption preparation of the present invention can stably maintain blood concentration of the active form of the present invention and is safe since there are no side effects. Therefore, it can be used as a percutaneous absorption preparation which can be persistently administered.Type: ApplicationFiled: April 27, 2006Publication date: March 19, 2009Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akio Nishiura, Hikaru Sugihara, Harumi Arai, Toshiya Kanaji
-
Patent number: 7504114Abstract: Preparations for percutaneous absorption comprising a basic drug or its salt dissolved in a liquid component and having an enhanced percutaneous absorbability and a safety to the skin, i.e., the administration site. The preparations for percutaneous absorption, preferably patches, contain a basic drug or its salt, an organic acid or its salt and a liquid component having a solubility parameter of from 7 to 13 (cal/cm3)1/2 and a have a very excellent skin permeability of the drug.Type: GrantFiled: April 7, 2000Date of Patent: March 17, 2009Assignee: Hisamitsu PharmaceuticalsInventors: Hisakazu Kurita, Tetsuro Tateishi, Tatsuaki Suzuki, Naruhito Higo
-
Publication number: 20090062720Abstract: An integrated iontophoresis skin-worn patch and method for delivering a therapeutically effective amount of a corticosteroid drug compound in a systemically-safe and skin-safe manner for site-specific treatment of inflammation pain is disclosed.Type: ApplicationFiled: August 27, 2008Publication date: March 5, 2009Applicant: TRAVANTI PHARMA INC.Inventors: Carter R. Anderson, Russell L. Morris, Robert Cohen, William V. Fowler
-
Publication number: 20090060986Abstract: Disclosed are bupivacaine transdermal delivery systems, and related methods.Type: ApplicationFiled: October 29, 2007Publication date: March 5, 2009Inventors: Su II Yum, Sung Yun Kwon, Xiaoping Song, James E. Brown
-
Publication number: 20090053290Abstract: Transdermal delivery compositions and topical compositions for application to the skin are provided. The transdermal delivery composition includes at least two penetrants working synergistically but by disparate biochemical pathways. In one embodiment, the transdermal delivery system includes benzyl alcohol and lecithin organogel. The transdermal delivery compositions are used in a variety of topical compositions as a means of transdermally delivering and topically administering different drugs and agents, including compositions promoting collagen biosynthesis, retinoids and skin lighteners, chemical denervation agents such as BOTOX®, anti-fungal agents, anesthetics and non-steroidal anti-inflammatory drugs (NSAIDs). In addition, these topical compositions may be used in combination with non-ablative treatment modalities, such as microdermabrasion, laser-based skin remodeling and radio-frequency-based skin remodeling.Type: ApplicationFiled: March 8, 2007Publication date: February 26, 2009Inventors: Bruce J. Sand, Michael Babich, Ali Zendedel Haghighi
-
Publication number: 20090053289Abstract: The present invention is a kit for use by a person to apply a daily treatment of medication and therapy to remove a corn or callus from the person's skin while providing maximum comfort to the person and minimal damage to healthy skin. In one embodiment, the kit comprises a box, an AM treatment system, and a PM treatment system for application at night. The AM treatment system comprises a plurality of AM foam bandages each having a medicated foam pad of hydrocolloid. The PM treatment system comprises a plurality of PM foam protective covers and a plurality of PM medicated non-woven patches impregnated with salicylic acid. The PM treatment system allows the person to remove a single PM medicated patch, trim it to fit the shape of the corn, and position it as desired over the corn. The person may then remove a single PM foam protective cover and apply it over the PM medicated patch, covering it completely, thereby limiting migration of the salicylic acid to healthy skin.Type: ApplicationFiled: February 27, 2008Publication date: February 26, 2009Inventor: Alan E. Nash
-
Publication number: 20090047334Abstract: The present invention relates to a method for delivery of calcium that avoids the problems with orally given calcium tablets. Particularly, the present invention is a transdermal patch for providing between 40 mg and 500 mg of bioavailable calcium to a patient.Type: ApplicationFiled: August 12, 2008Publication date: February 19, 2009Inventor: Patricia Williams
-
Publication number: 20090041832Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Type: ApplicationFiled: September 29, 2008Publication date: February 12, 2009Inventors: Sharad K. Govil, Ludwig J. Weimann
-
Publication number: 20090035357Abstract: A method of drug delivery utilizes a transdermal device that contains a phase change material and a first material such as a drug, a pharmaceutical, or a medicament mixed with or disposed near the phase change material. The phase change material is one that transitions from solid to liquid form when heated. A second material is disposed, suspended, or held in the solid form of the phase change material. The phase change material changes to a liquid state in response to heat and the second material that is disposed, suspended, or held in the phase change material is released and comes into contact with the first material. Advantageously, such second materials may include substances such as pharmaceuticals that boost or supplement the effect produced by a drug delivered transdermally by the device, or drug antagonists, or nicotine.Type: ApplicationFiled: August 8, 2008Publication date: February 5, 2009Applicant: ARIZANT HEALTHCARE INC.Inventor: Albert Philip Van Duren
-
Patent number: 7485623Abstract: A method of treatment comprises administering 4-hydroxy tamoxifen percutaneously to a patient having dense breast tissue. The 4-hydroxy tamoxifen may be formulated in a hydroalcoholic gel or an alcoholic solution.Type: GrantFiled: December 15, 2003Date of Patent: February 3, 2009Assignee: Laboratoires Besins International SAInventor: Jay Bua
-
Patent number: 7479132Abstract: The present invention discloses a patch for use in administration of an ionic medicine into a living body by infiltration of the ionic medicine into the living body through the living body surface without voltage application, characterized in that the patch comprises an ion-exchange membrane having a surface roughness (Rz) of 7 ?m or less at its part to be brought into contact with the living body surface and an ionic medicine impregnated into the ion-exchange membrane.Type: GrantFiled: March 9, 2004Date of Patent: January 20, 2009Assignee: Tokuyama CorporationInventors: Kenji Fukuta, Kanji Sakata
-
Publication number: 20090017102Abstract: The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.Type: ApplicationFiled: October 18, 2007Publication date: January 15, 2009Applicant: University of Kentucky Research FoundationInventors: Audra L. Stinchcomb, Peter A. Crooks, Mohamed O. Hamad, Paul K. Kiptoo
-
Publication number: 20090010998Abstract: The present invention provides a drug-delivery patch having at least one dissolvable layer comprising an active material and an adhesive backing or cover. The present invention also provides a method of transdermally vaccinating an animal by ablating an area of the stratum corneum of the animal and applying the patch described herein to the area.Type: ApplicationFiled: July 3, 2008Publication date: January 8, 2009Inventors: Kevin S. Marchitto, Stephen T. Flock
-
Publication number: 20090004257Abstract: A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.Type: ApplicationFiled: July 16, 2008Publication date: January 1, 2009Inventors: Subramanian S. Venkatraman, Shaoling Li, Robert M. Gale, Jane Stepic, William W. Van Osdol
-
Publication number: 20090005745Abstract: Systems for delivering an anti-inflammatory drug and methods for treating osteoarthritis are provided. Such systems can comprise, in one embodiment, a transdermal patch with a sufficient amount of anti-inflammatory drug in a formulation for sustained transdermal delivery at a human skin site. The system can further include a permeation composition or device, such as a heating device. The heating device can be configured for application over the transdermal patch and the human skin site. Further, the heating device can be configured for heating the human skin site to a specific temperature range from 36° C. to 42° C., and for maintaining the human skin site within that temperature range for a period of at least 4 or 5 hours.Type: ApplicationFiled: May 30, 2008Publication date: January 1, 2009Inventors: Jie Zhang, Kevin S. Warner
-
Publication number: 20090004250Abstract: This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use.Type: ApplicationFiled: September 10, 2008Publication date: January 1, 2009Inventor: Igor Gonda
-
Patent number: 7470433Abstract: The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent such as estradiol. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.Type: GrantFiled: March 30, 2007Date of Patent: December 30, 2008Assignee: Antares Pharma IPL AGInventors: Dario Norberto R. Carrara, Arnaud Grenier, Celine Besse, Stephen M. Simes, Leah M. Lehman
-
Patent number: RE40792Abstract: Compositions enriched with natural phyto-oestrogens or analogues thereof selected from Genistein, Daidzein, Formononetin and Biochanin A. These may be used as food additives, tablets or capsules for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia.Type: GrantFiled: May 19, 1993Date of Patent: June 23, 2009Assignee: Novogen Research Pty LtdInventor: Graham Edmund Kelly